JP2024129090A5 - - Google Patents

Download PDF

Info

Publication number
JP2024129090A5
JP2024129090A5 JP2024104635A JP2024104635A JP2024129090A5 JP 2024129090 A5 JP2024129090 A5 JP 2024129090A5 JP 2024104635 A JP2024104635 A JP 2024104635A JP 2024104635 A JP2024104635 A JP 2024104635A JP 2024129090 A5 JP2024129090 A5 JP 2024129090A5
Authority
JP
Japan
Prior art keywords
antibody
composition
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024104635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024129090A (ja
Filing date
Publication date
Priority claimed from JP2021542443A external-priority patent/JP7285936B2/ja
Application filed filed Critical
Publication of JP2024129090A publication Critical patent/JP2024129090A/ja
Publication of JP2024129090A5 publication Critical patent/JP2024129090A5/ja
Pending legal-status Critical Current

Links

JP2024104635A 2019-01-22 2024-06-28 Il-7rアルファサブユニットに対する抗体及びその使用 Pending JP2024129090A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962795378P 2019-01-22 2019-01-22
US62/795,378 2019-01-22
US201962868791P 2019-06-28 2019-06-28
US62/868,791 2019-06-28
JP2021542443A JP7285936B2 (ja) 2019-01-22 2020-01-21 Il-7rアルファサブユニットに対する抗体及びその使用
JP2023083769A JP7514363B2 (ja) 2019-01-22 2023-05-22 Il-7rアルファサブユニットに対する抗体及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023083769A Division JP7514363B2 (ja) 2019-01-22 2023-05-22 Il-7rアルファサブユニットに対する抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2024129090A JP2024129090A (ja) 2024-09-26
JP2024129090A5 true JP2024129090A5 (enExample) 2024-12-25

Family

ID=69726726

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021542443A Active JP7285936B2 (ja) 2019-01-22 2020-01-21 Il-7rアルファサブユニットに対する抗体及びその使用
JP2023083769A Active JP7514363B2 (ja) 2019-01-22 2023-05-22 Il-7rアルファサブユニットに対する抗体及びその使用
JP2024104635A Pending JP2024129090A (ja) 2019-01-22 2024-06-28 Il-7rアルファサブユニットに対する抗体及びその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2021542443A Active JP7285936B2 (ja) 2019-01-22 2020-01-21 Il-7rアルファサブユニットに対する抗体及びその使用
JP2023083769A Active JP7514363B2 (ja) 2019-01-22 2023-05-22 Il-7rアルファサブユニットに対する抗体及びその使用

Country Status (19)

Country Link
US (3) US11008395B2 (enExample)
EP (1) EP3914622A1 (enExample)
JP (3) JP7285936B2 (enExample)
KR (2) KR102570405B1 (enExample)
CN (2) CN118894938A (enExample)
AU (2) AU2020210635B2 (enExample)
BR (1) BR112021014106A2 (enExample)
CA (1) CA3127236A1 (enExample)
CL (1) CL2021001920A1 (enExample)
CO (1) CO2021010945A2 (enExample)
IL (1) IL285023A (enExample)
MX (1) MX2021008796A (enExample)
PE (1) PE20212305A1 (enExample)
PH (1) PH12021551783A1 (enExample)
SA (1) SA521422581B1 (enExample)
SG (1) SG11202107951YA (enExample)
TW (1) TWI872043B (enExample)
WO (1) WO2020154293A1 (enExample)
ZA (1) ZA202105394B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118894938A (zh) 2019-01-22 2024-11-05 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
BR112022001273A2 (pt) * 2019-08-02 2022-06-07 Univ California Composições e métodos para direcionar e matar células tronco cancerosas (cscs) positivas para alfa-v beta-3 (avss3) (cscs) e tratar cânceres metastáticos e resistentes a fármacos
US20220389104A1 (en) 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
KR20260110092A (ko) * 2023-07-31 2026-07-14 큐32 바이오 인크. 탈모 장애의 치료
JP2026526546A (ja) * 2023-07-31 2026-08-07 キュー32・バイオ・インコーポレーテッド アトピー性皮膚炎の治療
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
AU2024365145A1 (en) * 2023-10-26 2026-05-07 National Cancer Center Antibody against interleukin-7 receptor (il-7r), and antibody-drug conjugate (adc) including said antibody
WO2025098341A1 (en) * 2023-11-10 2025-05-15 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. IL-7Ra TARGETING ANTIBODIES AND USES THEREOF
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN118406118B (zh) * 2024-05-30 2025-01-21 重庆大学 一种靶向il-7r的小蛋白sbp003501及其制备方法和应用
WO2026022216A1 (en) 2024-07-23 2026-01-29 Ose Immunotherapeutics Uses of anti-cd127 antibodies in the treatment of inflammatory bowel diseases
WO2026033132A1 (en) 2024-08-09 2026-02-12 Twain Therapeutics Pte. Ltd. Antigen-binding molecules
WO2026062296A1 (en) 2024-09-23 2026-03-26 Ose Immunotherapeutics Therapy by antagonizing il-7 or cd127, and il-12, il-23, il-12r or il-23r
WO2026132078A1 (en) 2024-12-17 2026-06-25 Ose Immunotherapeutics Uses of anti-cd127 antibodies in the treatment of patients suffering from an inflammatory bowel disease and at high risk of relapse

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FI915911A7 (fi) 1989-06-15 1991-12-16 Immunex Corp Interleukiini-7-reseptoreja
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2141540A1 (en) 1993-06-01 1994-12-08 Satomi Nishikawa Monoclonal antibody, method for preparing the same and use of the same
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
JPH08507549A (ja) 1993-12-27 1996-08-13 バクスター、インターナショナル、インコーポレイテッド 水溶性の非免疫原性ポリアミド架橋剤
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
JP2004532038A (ja) 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
KR20030033007A (ko) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
JP4762156B2 (ja) 2004-01-12 2011-08-31 アプライド モレキュラー エボリューション,インコーポレイテッド Fc領域変異体
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
BRPI0510909A2 (pt) 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
WO2006052660A2 (en) 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Il-7 receptor blockade to suppress immunity
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EA016577B1 (ru) 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
BRPI0619331A2 (pt) 2005-10-26 2011-09-27 Medarex Inc método para fazer um composto para preparar um análogo de cbi cc-1065, método para preparar um análogo de cbi cc-1065 e composto
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
JP2010519310A (ja) 2007-02-21 2010-06-03 メダレックス インコーポレイテッド 単一のアミノ酸を有する化学リンカーおよびその複合体
DE102007036200A1 (de) 2007-08-02 2009-02-05 Knorr-Bremse Systeme für Nutzfahrzeuge GmbH Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech
CN101918027A (zh) 2007-11-02 2010-12-15 森托科尔奥索生物科技公司 半合成GLP-1肽-Fc融合构造、方法及其用途
EP3456191A1 (en) 2008-06-27 2019-03-20 Merus N.V. Antibody producing non-human mammals
TW201018482A (en) * 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
WO2010085643A1 (en) 2009-01-22 2010-07-29 University Of Miami Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders
WO2011072204A1 (en) 2009-12-10 2011-06-16 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
CA2787070A1 (en) * 2010-01-28 2011-08-04 Ian Kirby Cd127 binding proteins
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
AR080291A1 (es) * 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
MY195217A (en) 2010-06-22 2023-01-11 Regeneron Pharma MICE Expressing An Immunoglobulin Hybrid Light Chain
US20130295111A1 (en) 2010-08-10 2013-11-07 The Scripps Research Institute Methods and compositions for treating disorders associated with hyperactive immune system
EP2583980A1 (en) * 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
EP4050026A1 (en) * 2014-04-01 2022-08-31 Adimab, LLC Method of obtaining or identifying one or more common light chains for use in preparing a multispecific antibody
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
US20170247460A1 (en) 2014-10-18 2017-08-31 Pfizer Inc. Anti-il-7r antibody compositions
AR103268A1 (es) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
AU2016335750B2 (en) 2015-10-07 2023-05-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
US20190358258A1 (en) 2015-10-09 2019-11-28 Robert J. Deans Methods for enhancing proliferation of t regulatory cells
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
CN110392695B (zh) * 2016-12-09 2021-02-02 Ose免疫疗法 针对cd127的抗体和多肽
CN118894938A (zh) 2019-01-22 2024-11-05 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途

Similar Documents

Publication Publication Date Title
JP5795167B2 (ja) 疾患治療剤
Reichert Monoclonal antibodies as innovative therapeutics
JP2012524071A5 (enExample)
JP2023134618A5 (enExample)
JP2019162105A5 (enExample)
RU2011145428A (ru) АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
JP2022518770A5 (enExample)
JP2021101720A5 (enExample)
JP2021530229A5 (enExample)
JP2016505556A5 (enExample)
JP2019505527A5 (enExample)
RU2018129874A (ru) Антитела против фактора свертывания xi
JP2016529882A5 (enExample)
JP2018519364A5 (enExample)
RU2010138567A (ru) Антитела рецептора 1 интерферона альфа и их применение
JP2006502699A5 (enExample)
JP2025004013A5 (enExample)
WO2022105914A1 (zh) Cd70抗体及其应用
CA3177961A1 (en) Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
RU2016136639A (ru) Антитела против эотаксина 2, которые распознают дополнительные связывающие CCR3 хемокины
JP2024541680A5 (enExample)
KR20130028055A (ko) Cd 127 결합 단백질
US11359010B2 (en) Humanized anti-S100A9 antibody and uses thereof
JP2026048732A5 (enExample)
JP2025508835A5 (enExample)